Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal several positive indicators, such as strong international growth, effective bundling strategies, and stable market sentiment despite competition. The company maintains healthy margins and anticipates FDA approval for new products. While some responses lacked specificity, the overall sentiment is optimistic, with guidance aligning with consensus estimates and expected growth in key markets. These factors suggest a likely positive stock price movement over the next two weeks.
Key Financial Performance
Global Net Revenue $73.1 million, representing a 7% increase over the prior year. This included $66.4 million of global Jeuveau revenue and $6.7 million from Evolysse. The increase was driven by healthy underlying demand and unit growth in both U.S. and international markets.
Jeuveau Global Revenue $66.4 million in the first quarter. Units increased in both U.S. and international markets, reflecting healthy underlying demand. However, U.S. revenue was impacted by onetime revenue deferral dynamics that benefited the first quarter of 2025 and created a headwind in the first quarter of 2026.
Evolysse Revenue $6.7 million in the first quarter. This reflects increasing relevance with customers and an evolving revenue mix as the company applies the same playbook that drove Jeuveau's success.
Adjusted Gross Margin 68%, excluding the amortization of intangibles. This reflects the company's ability to maintain cost efficiency and scale the business.
GAAP Operating Expenses $55.7 million in the first quarter compared to $55.1 million in the fourth quarter of 2025. The increase was due to the absence of a $4.5 million benefit related to the revaluation of the contingent royalty obligation in the prior quarter.
Non-GAAP Operating Expenses $49.1 million in the first quarter compared to $53 million in the fourth quarter of 2025. This reflects continued discipline and the impact of structural cost actions implemented in 2025.
Adjusted EBITDA Positive $0.6 million in the first quarter compared to a loss of $5.5 million in the prior year period. This improvement reflects both revenue growth and improved cost efficiency.
Cash and Cash Equivalents $49.8 million at the end of the first quarter compared to $53.8 million at the end of the fourth quarter. The decrease was primarily due to interest and bonus payments, offset by net proceeds from the line of credit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Jeuveau: Delivered $66.4 million in global revenue in Q1 2026 with positive unit growth and pricing stability across U.S. and international markets. Expected high single-digit growth for Jeuveau in the first half of 2026.
Evolysse: Contributed $6.7 million in revenue in Q1 2026. Accounts are repurchasing at higher volumes, and customer feedback is positive.
Estyme: Planned launch in Europe in mid-May 2026, including a full line of products such as Sculpt Mid-Face, Smooth, Form, and Lips.
Sculpt: FDA approval expected in Q4 2026, which will strengthen competitive positioning in the RHA market.
U.S. Toxin Market: Grew in the low to mid-single digits in Q1 2026. Jeuveau maintained a 14% market share.
International Expansion: Steady growth with the upcoming launch of Estyme in Europe and continued success with Nuceiva.
Digital Ecosystem: Integrated platform connects practice engagement, product ordering, consumer acquisition, loyalty, and repeat utilization. Embedded AI improves targeting, field productivity, and decision-making.
Portfolio Bundling Strategy: Structured 6-month program showing increasing traction and contributing to growth and profitability.
Cost Structure Alignment: Deliberate actions in 2025 have positioned the company for sustained profitability and operational leverage.
Long-term Strategy: Focused on building a scaled multiproduct aesthetics company with a differentiated business model. Strategy includes expanding account coverage, improving field productivity, and deepening customer relationships.
Innovation Pipeline: Actively evaluating capital-efficient opportunities to complement the portfolio and leverage existing infrastructure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs on South Korean pharmaceutical products: A 15% tariff on certain pharmaceutical products from South Korea, including Jeuveau, is set to take effect on September 29, 2026. This could impact costs and profitability, though the company is exploring mitigation strategies.
Revenue deferral dynamics: Onetime revenue deferral dynamics created a headwind in the first quarter of 2026, impacting reported revenue growth.
Seasonality and timing dynamics: Seasonal and prior-year timing dynamics affected reported revenue, particularly for Jeuveau, creating challenges in maintaining consistent growth.
Regulatory hurdles for new product approvals: The company is awaiting FDA approval for Sculpt in the fourth quarter of 2026, which is critical for strengthening its competitive position in the RHA market.
Inventory management challenges: The company plans to secure significant U.S. inventory to mitigate the impact of upcoming tariffs, which could strain resources and operational flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects total net revenue of $327 million to $337 million for the full year 2026, representing double-digit revenue growth. Jeuveau is expected to achieve high single-digit growth in the first half of 2026.
Adjusted EBITDA Profitability: The company aims to achieve full-year adjusted EBITDA profitability in 2026, with a low to mid-single-digit adjusted EBITDA margin.
Gross Margin: Adjusted gross margin is projected to be between 65.5% and 67% for the full year 2026.
Operating Expenses: Non-GAAP operating expenses are expected to range from $210 million to $216 million for the full year 2026.
Product Launches and Pipeline: The company plans to launch Estyme in Europe in mid-May 2026 and expects FDA approval for Sculpt in the fourth quarter of 2026. Additionally, the company is actively pursuing targeted capital-efficient opportunities to expand its innovation pipeline.
Market Expansion: The company is expanding its addressable market internationally with the launch of Estyme in Europe and building on the commercial foundation established with Nuceiva.
Tariff Mitigation: The company is actively evaluating options to mitigate or eliminate the impact of a 15% tariff on certain pharmaceutical products from South Korea, effective September 29, 2026. A plan to secure significant U.S. inventory is in place, and updates will be provided by year-end.
Long-Term Outlook: The company maintains its long-term outlook through 2028, expecting continued double-digit revenue growth, significant margin expansion, and increasing operating leverage.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you find the headwinds of the filler market impacting the Evolysse launch? Is bundling helping with increasing volumes? Is any of the bundling taking away from net sales?
A:David Moatazedi explained that the sentiment in the filler market is turning more positive, with rising interest and utilization of HAs. Although the market may still be slightly down year-on-year, it has improved compared to 1-2 years ago. Evolysse is gaining traction as clinicians gain experience and confidence, leading to increased reorder rates. Bundling, including a growth rebate program, has been effective in encouraging clinics to partner more closely with Evolus, with good uptake observed. More quantitative data will be shared in the Q2 earnings call.
Q:Is your rebate different from your competitors? Is it more of a direct cash savings than a rebate that goes towards forward sales?
A:David Moatazedi stated that the rebate operates similarly to competitors, where clinics earn back amounts on their accounts. However, Evolus designed it as a partnership rebate based on growth with Evolus, incentivizing clinics to convert their portfolio business to Evolus. Tatjana Mitchell added that the rebate does not drag on net sales and is designed to maintain healthy margins.
Q:Can you give us a sense of what's going on OUS (outside the U.S.) for both toxins and fillers? What is the dynamic there, country by country?
A:David Moatazedi highlighted strong performance in OUS markets, with revenue nearly doubling in some areas. The U.K., the most mature market, is approaching double-digit growth, while other European markets show significant growth potential. The launch of Estyme in Europe is expected to benefit from the infrastructure and presence established there. Overall, all markets are experiencing healthy growth, and the international business is expected to grow to 15% of overall revenue.
Q:What is the impact of Hugel entering the U.S. market as a competitor? Are they doing anything differently now compared to six months ago?
A:David Moatazedi noted that despite Hugel's entry and initial heavy sampling, Evolus continues to gain market share. He expects another competitor to enter in the back half of the year, but no major share shift dynamics have been observed.
Q:Is it fair to think about a rebound or reacceleration for Jeuveau in Q2? Does the high single-digit first-half growth for Jeuveau align with consensus estimates?
A:Tatjana Mitchell explained that the quarter-over-quarter revenue for Jeuveau reflects normal seasonality. The high single-digit growth guidance for the first half of the year aligns with consensus estimates, despite unusual dynamics in the prior year.
Q:Have you seen further signs of recovery in Europe and the U.S. for fillers? How are fillers performing versus biostimulators? What are your assumptions on competitive launches?
A:David Moatazedi stated that the filler market in Europe is more resilient than in the U.S. due to a stronger economic backdrop. The HA market in Europe may have turned positive by year-end. Assumptions for competitive launches include Galderma introducing a new liquid toxin in the back half of the year, while short-acting products are not expected to impact revenue significantly.
Q:How should we think about stress testing the macro environment in terms of the broader aesthetics market?
A:David Moatazedi emphasized that despite macroeconomic challenges, the aesthetics market remains stable and strong. Consumer sentiment is positive, and transactional data from the Evolus Rewards program indicates continued strength in product utilization.
Q:What is your perspective on the filler market and its dynamics, including competition and consumer behavior?
A:David Moatazedi noted that the filler market is in recovery, with new consumers entering due to trends like GLP-1 patients seeking aesthetic treatments. The market is expected to return to positive growth, driven by differentiation of Evolysse, training, and competitive bundling strategies.
Q:Should we expect any initial stocking order for Estyme similar to Evolysse in Q2 of last year?
A:Tatjana Mitchell mentioned that while some initial stocking is expected for Estyme, it will not have a meaningful impact on Q2 growth due to the market size and mid-quarter launch.
Q:What feedback or communications have you had with the FDA on Sculpt?
A:Rui Avelar stated that the Sculpt PMA process is ongoing, with regular interactions with the FDA. Approval is expected by Q4, though timelines could vary.
Q:What kind of products are you interested in for business development, and how large of a transaction could we see?
A:David Moatazedi and Rui Avelar highlighted interest in biostimulators, skin quality products, and hair-related treatments. They are actively evaluating assets with a focus on differentiation and unmet needs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantitative data on the impact of bundling on net sales, stating that more details would be shared in the Q2 earnings call. Additionally, they did not provide clear visibility into the first-quarter performance of the HA market in Europe, only suggesting it may have improved. The response regarding Sculpt's FDA approval timeline was also vague, with no definitive commitment to a specific date.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Europe
FDA
RHA
Sculpt
account
approach
benefit
capability
capital
cash
confidence
credit
demand dynamic
differentiation
digit margin
discipline cost
efficiency
engagement
facility
field productivity
launch Estyme
leverage
low digit
market
model
momentum
multiproduct
opportunity
outlook
plan
platform
portfolio
practice
profitability
progress
scale
share
structure
tariff
term
EOLS Transcript
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary and Q&A reveal several positive indicators, such as strong international growth, effective bundling strategies, and stable market sentiment despite competition. The company maintains healthy margins and anticipates FDA approval for new products. While some responses lacked specificity, the overall sentiment is optimistic, with guidance aligning with consensus estimates and expected growth in key markets. These factors suggest a likely positive stock price movement over the next two weeks.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Positive3-4
Evolus reported strong financial performance with a 25% YoY revenue increase and improved gross margins. Net income turned positive, reflecting effective cost management. Despite no mention of dividends or buybacks, the solid growth figures and profitability improvements are positive indicators. The absence of negative Q&A feedback further supports a positive sentiment. However, lack of market cap data limits precise prediction.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
EOLS Slides
EOLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
